Rigel Pharmaceuticals Valuation
Is RI2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RI2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RI2 (€26.4) is trading above our estimate of fair value (€13.21)
Significantly Below Fair Value: RI2 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RI2?
Key metric: As RI2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is RI2's PE Ratio? | |
|---|---|
| PE Ratio | 126.5x |
| Earnings | US$3.88m |
| Market Cap | US$491.11m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.4x |
| Enterprise Value/EBITDA | 46.8x |
| PEG Ratio | 2.9x |
Price to Earnings Ratio vs Peers
How does RI2's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14.7x | ||
FYB Formycon | 13.8x | 32.4% | €882.8m |
BIO3 Biotest | 15.4x | 29.3% | €1.3b |
2INV 2invest | 12.8x | n/a | €64.4m |
PSG PharmaSGP Holding | 16.7x | 13.9% | €304.6m |
RI2 Rigel Pharmaceuticals | 126.5x | 43.3% | €491.1m |
Price-To-Earnings vs Peers: RI2 is expensive based on its Price-To-Earnings Ratio (126.5x) compared to the peer average (14.7x).
Price to Earnings Ratio vs Industry
How does RI2's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: RI2 is expensive based on its Price-To-Earnings Ratio (126.5x) compared to the European Biotechs industry average (26.5x).
Price to Earnings Ratio vs Fair Ratio
What is RI2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 126.5x |
| Fair PE Ratio | 22.2x |
Price-To-Earnings vs Fair Ratio: RI2 is expensive based on its Price-To-Earnings Ratio (126.5x) compared to the estimated Fair Price-To-Earnings Ratio (22.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €26.40 | €27.62 +4.6% | 59.1% | €53.98 | €13.26 | n/a | 6 |
| Nov ’25 | €12.80 | €24.49 +91.3% | 61.1% | €52.18 | €10.53 | n/a | 6 |
| Oct ’25 | €13.90 | €24.49 +76.2% | 61.1% | €52.18 | €10.53 | n/a | 6 |
| Sep ’25 | €11.90 | €24.49 +105.8% | 61.1% | €52.18 | €10.53 | n/a | 6 |
| Aug ’25 | n/a | €18.36 0% | 46.8% | €36.86 | €11.06 | n/a | 6 |
| Jul ’25 | €7.72 | €19.00 +146.1% | 44.3% | €37.38 | €13.55 | n/a | 6 |
| Jun ’25 | €8.65 | €41.76 +382.8% | 105.0% | €138.18 | €13.36 | n/a | 6 |
| May ’25 | €9.89 | €42.41 +329.0% | 103.7% | €139.31 | €15.32 | n/a | 6 |
| Apr ’25 | €13.42 | €40.91 +204.9% | 107.9% | €137.66 | €9.18 | n/a | 6 |
| Mar ’25 | €14.12 | €38.12 +170.1% | 118.8% | €138.62 | €9.24 | n/a | 6 |
| Feb ’25 | €10.87 | €37.90 +248.7% | 122.3% | €140.67 | €9.38 | n/a | 6 |
| Jan ’25 | €13.82 | €37.90 +174.3% | 122.3% | €140.67 | €9.38 | n/a | 6 |
| Dec ’24 | €10.24 | €37.90 +270.3% | 122.3% | €140.67 | €9.38 | n/a | 6 |
| Nov ’24 | €7.33 | €38.16 +420.5% | 116.6% | €137.10 | €11.88 | €12.80 | 6 |
| Oct ’24 | €10.21 | €38.16 +273.7% | 116.6% | €137.10 | €11.88 | €13.90 | 6 |
| Sep ’24 | €10.31 | €38.16 +270.1% | 116.6% | €137.10 | €11.88 | €11.90 | 6 |
| Aug ’24 | €12.11 | €38.13 +214.9% | 117.3% | €137.55 | €11.00 | n/a | 6 |
| Jul ’24 | €12.01 | €38.13 +217.5% | 117.3% | €137.55 | €11.00 | €7.72 | 6 |
| Jun ’24 | €12.75 | €38.13 +199.2% | 117.3% | €137.55 | €11.00 | €8.65 | 6 |
| May ’24 | €10.03 | €38.13 +280.4% | 117.3% | €137.55 | €11.00 | €9.89 | 6 |
| Apr ’24 | €12.33 | €42.82 +247.2% | 114.1% | €139.92 | €11.19 | €13.42 | 5 |
| Mar ’24 | €14.00 | €34.79 +148.5% | 127.5% | €142.41 | €8.54 | €14.12 | 7 |
| Feb ’24 | €15.00 | €34.79 +131.9% | 127.5% | €142.41 | €8.54 | €10.87 | 7 |
| Jan ’24 | €12.65 | €34.79 +174.9% | 127.5% | €142.41 | €8.54 | €13.82 | 7 |
| Dec ’23 | €6.34 | €35.92 +466.5% | 131.6% | €150.56 | €8.03 | €10.24 | 7 |
| Nov ’23 | €7.75 | €38.27 +394.2% | 123.7% | €151.94 | €10.13 | €7.33 | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Aspen Pharmacare Holdings
R73.7b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.60
7D
-3.9%
1Y
-0.6%
Collegium Pharmaceutical
US$990.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
1.4%
1Y
25.0%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
-1.0%
1Y
-31.3%